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Background: 14-3-3σ is a homo-dimeric 
protein important for drug and radiation 
resistance. 
Results: Mutation of single hydrophobic core 
residue results in non-functional monomeric 
proteins. 
Conclusion: Hydrophobic core residues are 
important for 14-3-3σ dimerization and 
homo-dimerization is required for its function. 
Significance: Identifying important 
hydrophobic core residues for homo-
dimerization may help drug the “undruggable” 
protein dimers such as 14-3-3σ. 
SUMMARY 
Many proteins exist and function as homo-
dimers. Understanding the detailed 
mechanism driving the homo-dimerization 
is important and will impact future studies 
targeting the “undruggable” oncogenic 
protein dimers. In this study, we used 14-
3-3σ as a model homo-dimeric protein and 
performed a systematic investigation of the 
potential roles of amino acid residues in 
the interface for homo-dimerization. 
Unlike other members of the conserved 14-
3-3 protein family, 14-3-3σ prefers to form 
homo-dimer with two subareas in the 
dimeric interface that has 180o symmetry. 
We found that both subareas of the 
dimeric interface are required to maintain 
full dimerization activity. While the 
interfacial hydrophobic core residues 
Leu12 and Tyr84 play important roles in 14-
3-3σ dimerization, the non-core residue 
Phe25 appears to be more important in 
controlling 14-3-3σ dimerization activity. 
Interestingly, a similar non-core residue 
Val81 is less important than Phe25 in 
contribution to 14-3-3σ dimerization. 
Furthermore, dissociating dimeric 14-3-3σ 
into monomers by mutating the 
dimerization residues Leu12, Phe25, or 
Tyr84 individually diminished the function 
of 14-3-3σ in resisting drug-induced 
apoptosis and in arresting cells at G2/M 
phase in response to DNA-damaging 
treatment. Thus, dimerization appears to 
be required for the function of 14-3-3σ. 
14-3-3σ is a member of the highly 
conserved mammalian 14-3-3 protein family 
that function as chaperons (1-3) and bind to a 
variety of proteins important for various 
cellular processes (4) including cytokinesis 
(5), cell cycle regulation (6-9), and apoptosis 
(8,10-12). Because of its roles in multiple 
cellular processes, 14-3-3σ has been 
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considered as a double-edged sword of 
cancers (1). Silencing the expression of 14-3-
3σ may contribute to tumorigenesis (13,14) 
while its up-regulation in cancers causes 
resistance to chemotherapy (8,15,16). 
The atomic structure of 14-3-3σ has 
been determined (4,17) to have an overall 
dimeric structure that resembles a flattened 
horseshoe (1). Each subunit of the dimer 
consists of 9 α-helices. Unlike most other 14-
3-3 proteins that can form both homo- and 
hetero-dimers among the 14-3-3 family 
proteins, 14-3-3σ prefers to form only homo-
dimers (17). It has also been found that 
mutation of Ser5, Glu20 and Glu80 residues 
promoted hetero-dimerization of 14-3-3σ 
with other 14-3-3 isoforms while mutations 
of the Phe25 and Gln55 residues promoted 
little hetero-dimerization although they 
decreased the ability of 14-3-3σ to form 
homo-dimers (18). Interestingly, the 
combined mutations of all five residues 
resulted in a mutant that could no longer 
form homo-dimer but could form hetero-
dimers with all other six 14-3-3 isoforms. 
In a recent study analyzing 
mechanisms of 14-3-3σ dimerization using 
molecular dynamic (MD) simulations and 
site-directed mutagenesis (19), we found that 
Phe25 is critical in packing and stabilizing 
hydrophobic core residues that are important 
for dimerization by organizing co-operativity 
of core and other residues for favorable 
hydrophobic and electrostatic interactions. 
This organizing activity of Phe25 for 14-3-3σ 
homo-dimerization is bestowed from its 
unique physical location, rigidity, size, and 
hydrophobicity.  
In this study, we performed a 
systematic study of the amino acid residues 
in the hydrophobic core of the 14-3-3σ 
dimeric interface along with residues not 
located in the hydrophobic core for their 
potential role in 14-3-3σ dimerization and 
investigated the potential effect of the 
mutations of these residues on 14-3-3σ 
function. We have identified amino acid 
residues that are important to maintain the 
dimerization activity of 14-3-3σ and shown 
that dimerization is required for the function 
of 14-3-3σ in contributing drug and radiation 
resistance. 
Experimental Procedures 
Cell culture and transfection. 
HEK293 cells were cultured in DMEM 
supplemented with 10% fetal bovine serum 
[Invitrogen] and 1% penicillin/ streptomycin 
[BioWhittaker]. Mia PaCa-2 cells were 
cultured in DMEM supplemented with 10% 
fetal bovine serum, 2.5% equine serum 
[Hyclone] and 1% penicillin/streptomycin. 
Transient and stable of 14-3-3σ transfection 
were performed with Lipofectamine 
[Invitrogen] as we previously described (20). 
Stable transfectants were generated by 
selection using 1mg/ml G418 for 2 weeks 
and then single clones were selected and 
maintained in the presence of 200ug/ml G418. 
The protein levels of 14-3-3σ in the stable 
clones were continuously monitored using 
Western blot.  
Construct engineering. Wild type and 
mutant 14-3-3σ constructs with different tags 
(Flag, HA, Myc, and HAM2) were 
engineered using PCR and QuickChange® 
Site-Directed Mutagenesis Kits as we 
previously described (8,15,19-21). The 
primer pairs used for each construct are 
shown in Table 1.  
In-vitro transcription and translation. 
In-vitro transcription and translation were 
performed as previously described (22,23). 
Briefly, 14-3-3σ constructs were linearizated 
using XhoI, followed by in vitro transcription 
using T7 RNA polymerase. The in-vitro 
transcripts were then purified and used to 
program cell-free translation in rabbit 
reticulocyte lysate. The reactions were 
stopped by incubation at 65°C for 5min and 
subjected to co-immunoprecipitation and 
Western blot analysis.  
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Immunoprecipitation and Western 
blot analysis. Immunoprecipitation and 
Western blot analysis were performed as 
previously described (19,24,25). Briefly, cell 
lysates or in vitro translation products were 
precleared with protein A beads plus normal 
mouse IgG followed by incubation with 
primary HA (Convance), Myc (Cell 
Signaling), or Flag (Sigma) antibodies and 
protein A beads. The precipitated materials 
were washed extensively with with TNN 
buffer (50mM Tris·HCl, PH7.4, 150mM 
NaCl, 5% NP-40, 20mM EDTA, 50mM NaF, 
1mM Na3VO3, 1mM PMSF, 1mM DTT). 
The final precipitated materials were pelleted 
by centrifugation and solubilized for 
separation on SDS-PAGE followed by 
Western blot analysis probed using HA, Myc, 
Flag, or actin (Santa Cruz) antibodies. The 
images were captured with FlourchemHD2 
(Alpha Innotech corporation) after incubated 
with ECL (GE). 
Survival assay. Survival assay was 
performed as previously described using SRB 
(sulforhodamine B) or colony formation 
assays (20,26). Briefly, for SRB assay, 5000 
cells/well were seeded in 96-well plates and 
cultured overnight. The cells were then 
treated with various concentrations of 
mitoxantrone for three days followed by 
incubation with 0.4% (W/W) sulforhodamine 
B in 1% Acetic Acid (V/V) for 30 minutes at 
room temperature. Unbound sulforhodamine 
B was then removed by washing with 1% 
acetic acid for three times and cells were air 
dried. Finally, the bound sulforhodamine B 
was solubilized with in 10 mM Tris base and 
OD570nm was measured. For colony formation 
assay, cells were seeded 100 cells/well in 6 
well plates and cultured overnight. The cells 
were then treated with 2 Gy γ-irradiation 
followed by continuous culture for two 
weeks with media changed every 2-3 days. 
Cell colonies were stained with crystal violet 
and counted manually. Survival data was 
analyzed with GraphPad Prism 4.        
Cell cycle analyses. Cell cycle 
analysis was performed with propidium 
iodide (PI) staining and FACS as previously 
described (27). Briefly, 3×105cells were 
seeded in a 6-cm dish followed by treatment 
with 10 nM mitoxantrone or DMSO for three 
days. Cells were then collected and fixed in 
cold 75% ethanol and stained with 100ug/mL 
propidium iodide, followed by analysis with 
FACS (fluorescence-activated cell sorting). 
The data were analysed using Cell Quest and 
Modifit programs. 
Molecular Modeling and MD 
simulation. The structure with Pdb code 
1YWT from protein databank was used as the 
template structure for 14-3-3σ and missing 
loops were modeled by MOE with the 
homology modeling module. Mutations of 
specific residues were introduced by the 
UCSF Chimera swapaa function. MD 
simulations of mutant 14-3-3σ dimers were 
carried out using the AMBER9 package. 
FF03 parameters and hydrogen atoms were 
assigned to the protein by tleap module of 
AMBER9.  All dimers were solvated in a 84 
x 103 x 67 Å rectangular box. Appropriate 
number of counter ions was added to 
neutralize each system. Particle Mesh Ewald 
(PME) was employed to calculate the long-
range electrostatic interactions and the 
nonbonded cutoff was set to 8.0 Å.  
Each system was equilibrated by a 
four-step protocol prior to production MD 
simulation as previously described (19). The 
same conditions of the final equilibration step 
were used for 20-ns production MD 
simulations.  
To determine how each mutation 
affects 14-3-3σ dimerization, binding free 
energies between the two associating 
subunits were calculated using the GBSA 
method (28). The binding free energy is 
computed by taking the difference between 
the mm-GBSA free energy of the complex 
with that of the ligand and receptor: 
∆Gbind=Gcomplex-Greceptor-Gligand, where 
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G=Gsolute+Gsolvent. The Gsolute term for each 
system can be obtained by Gsolute=E-TS. E 
represents an average of energies obtained 
from MD simulation and is the sum of the 
following 3 terms: “non-bonded electrostatic 
energy + 1,4-electrostatic energy” (Eele); 
“non-bonded van der Waals energy + 1,4-van 
der Waals energy” (Evdw) and “bond, angle, 
dihedral energies” (Eint). S is the entropy 
contribution that is omitted from our 
calculation because the purpose of this study 
is to compare the effect of each mutation on 
dimerization rather than to calculate absolute 
binding free energy. The Gsolvent term can be 
obtained by Gsolvent=Ges+Gnes. G
es 
is the
electrostatic contribution that is obtained by 
the GB method, and G
nes 
is the non-
electrostatic contribution and is proportional 
to the solvent-accessible surface area of the 
molecule. As the entropy term is not included 
in this study, the calculated total binding free 
energy (∆Gbind) only consists of the E and 
Gsolvent terms. A total of 100 snapshots were 
collected from the production trajectory for 
MM-GBSA free energy calculations. Grid 
size was set as 0.5 Å, and the dielectric 
constants for the solute and solvent were set 
as 1 and 80, respectively. RMSF of 
interfacial core residues were calculated by 
the atomicfluct command of ptraj. 
Small-angle x-ray scattering (SAXS) 
analysis. SAXS was performed using 
beamline 12ID-B of Advanced Photon 
Sources (APS) at Argonne National 
Laboratory. The wavelength, , of x-ray 
radiation was set as 0.866 Å. Scattered x-ray 
intensities were measured using two detectors, 
Pilatus 2M and 300K (DECTRIS Ltd). The 
sample-to-detector distance was set such that 
the detecting range of momentum transfer q 
(=4 sin/, where 2 is the scattering angle) 
of SAXS experiments was 0.01-2.6 Å-1.  To 
reduce the radiation damage, a flow cell 
made of a cylindrical quartz capillary with a 
diameter of 1.5 mm and a wall of 10 µm was 
used and the exposure time was set to 1 
second. In order to obtain good signal-to-
noise ratios, twenty images were taken for 
each sample and buffer control.  The 2-D 
scattering images were converted to 1-D 
SAXS curves through azimuthally averaging 
after solid angle correction and then 
normalization with the intensity of the 
transmitted x-ray beam. The software 
package used for the conversion was 
developed at beamline 12ID-B. Undesired 
interactions among biomacromolecules have 
been corrected, if any, before data analysis. 
The radius of gyration (Rg) was calculated 
using the Guinier equation ܫሺݍሻ ൌ
ܫ݋	exp	ሺെܴ௚ଶݍଶ/3ሻ, where Io is the forward 
scattering (29). The pair distance distribution 
function (PDDF) that is roughly a weighted 
histogram of atomic-pair distance in the 
molecule, were calculated using GNOM (30).   
Results 
Analysis of the dimeric interface of 
14-3-3σ. To investigate the determinant 
residues of 14-3-3σ dimerization, we first 
examined the dimeric interface of 14-3-3σ 
(PDB code: 1YZ5 and 1YWT). The overall 
structure of 14-3-3σ  dimer is composed of 
nine helices, A through I, from each 
monomer (4,5). Helices A and B of one 
subunit interact with helices C and D of the 
opposing subunit, respectively, and vice 
versa. The 980 Å2 total buried interface can 
be divided into two structurally similar 
subareas, which are related by the pseudo-2-
fold symmetry of the protein (19). In each 
subarea, residues Lys9, Leu12, Ala13 and Ala16 
of one subunit and Ala58, Leu62, Tyr84 and 
Val88 of the opposing subunit form an 
interfacial core as defined previously (19) 
and all have >80% buried surface area in the 
dimeric interface (solvent accessible area in 
monomeric protein that becomes buried upon 
dimerization) (Table 2). The top two most 
buried core residues, Tyr84 and Leu12, have 
99 and 96% of their solvent accessible area 
buried in the dimeric interface, respectively, 
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and provide the highest level of buried 
surface areas (120 and 88 Å2, respectively).  
Contribution of Leu12, Phe25, Val81 
and Tyr84 to 14-3-3σ dimerization. To 
investigate the potentially important residues 
in 14-3-3σ dimerization, we chose to further 
investigate the top two core residues, Tyr84
and Leu12. We also selected two other 
hydrophobic residues, Phe25 and Val81, which 
have 40-50% of its solvent accessible area 
buried in the dimeric interface (Table 2) but 
are not located in the interfacial core. Gln8, 
which does not appear to contribute to 
dimerization from our analysis was chosen as 
a negative control residue.  
Next, all five residues were mutated 
to Gly since MD simulations have shown 
previously that the L12G, F25G, and Y84G 
mutations do not interrupt the stability of the 
helices they reside on despite that Gly is a 
potential helix breaker (19). A 3-ns MD 
simulation of the V81G and Q8G mutants also 
shows that these mutations do not disrupt the 
stability of their respective helices (data not 
shown). Therefore, the secondary structure of 
α-helices in these mutants may be maintained 
as in the wild type protein (see also below). 
Because the dimeric 14-3-3σ structure 
has an 180o-symmetry and each interfacial 
residue occurs twice, each residue contributes 
to two interactions with one from each 
subunit in two interfacial subareas (Fig. 1A). 
To determine the potential contribution of 
Leu12, Phe25, Val81 and Tyr84 to 14-3-3σ 
dimerization, we performed an experiment to 
determine if the mutant 14-3-3σ can dimerize 
with the wild type one using co-
immunoprecipitation. In this case, only one 
of the two interfacial subareas carries a 
mutation in the mutant subunit. We first 
engineered wild type 14-3-3σ tagged with an 
HA epitope (σ-HA, Fig. 1A) and mutant 14-
3-3σ tagged with an HA and two Myc 
epitopes (σ-HAM2, Fig. 1A), for convenience 
of detecting both wild type and mutant 
proteins using a common HA antibody and to 
differentiate them by ~3-kDa difference in 
size on Western blot. Next, we transiently 
transfected the HAM2-tagged mutant 
constructs into HEK-293 cells with stable 
expression of HA-tagged wild type 14-3-3σ. 
As shown in Fig. 1B (input), all HAM2-
tagged mutant constructs were well expressed 
along with the HA-tagged wild type 14-3-3σ. 
Co-immunoprecipitation was then performed 
using Myc antibody followed by Western 
blot analysis of the precipitate using HA 
antibody. Fig. 1B shows that HAM2-tagged 
Q8G and wild type 14-3-3σ co-precipitate 
HA-tagged wild type 14-3-3σ whereas the 
HAM2-tagged L12G, F25G, and Y84G mutants 
do not.  
Surprisingly, the HAM2-tagged V81G 
mutant also co-precipitated the HA-tagged 
wild type 14-3-3σ. Because Val81 and Phe25 
have similar buried surface area in dimeric 
interface (25 Å2 and 24 Å2, respectively) and 
these buried areas also occupy similar 
percentages (53% and 42%, respectively) of 
their total solvent accessible areas in the 
monomeric protein (Table 2), their 
contribution to dimerization was thought to 
be similar. However, this is clearly not the 
case as V81G but not F25G co-precipitated the 
wild type 14-3-3σ.  
To eliminate the possibility that above 
observations of 14-3-3σ dimerization is due 
to stable cell lines used, these constructs were 
used to program cell-free transcription and 
translation followed by co-
immunoprecipitation using Myc antibody and 
Western blot analysis using HA antibody. As 
shown in Fig. 1C, similar findings of co-
precipitation were observed with the HAM2-
tagged wild type, Q8G and V81G mutants 
while no co-precipitation was observed with 
HAM2-tagged L12G, F25G, and Y84G mutants. 
Thus, the differential dimerization activity of 
mutant 14-3-3σ is unlikely due to cell line or 
cell-free systems used.  
To further confirm the above 
observations, we next used a different 
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method of detection and performed a non-
denaturing PAGE separation of cell-free 
translation products of HA and HAM2-tagged 
wild type and F25G mutant 14-3-3σ followed 
by Western blot analysis probed with HA and 
Myc antibodies. To rule out the possible 
effect of mutation to Gly residue, we also 
created another mutant, F25E, for analysis. As 
shown in Fig. 2, HAM2- and HA-tagged wild 
type 14-3-3σ each alone formed a dimer with 
highest (HAM2/HAM2) and lowest (HA/HA) 
molecular weight, respectively (lanes 1 and 4, 
top panel). Co-translation of both HAM2- and 
HA-tagged wild type 14-3-3σ formed hetero-
dimers (HAM2/HA) between the two 
differentially tagged 14-3-3σ molecules with 
a mobility between HAM2/HAM2 and 
HA/HA homo-dimers (lane 5). However, 
F25G and F25E mutants alone could not form 
any detectable dimer by themselves (lanes 2-
3). Furthermore, co-translation of wild type 
and mutant 14-3-3σ generated only dimers of 
the HA-tagged wild type protein while the 
HAM2-tagged mutant 14-3-3σ stayed as 
monomers (lanes 6-7). Thus, we conclude 
that wild type 14-3-3σ likely prefers to bind 
to wild type 14-3-3σ and the Phe25 mutant 
14-3-3σ does not have affinity to the wild 
type protein or itself and that the mutation 
effect on dimerization is unlikely due to Gly 
residue used as a substitute residue.  
V81G mutation does not cause 
changes to the hydrophobic core residues in 
the dimeric interface of 14-3-3σ. Previously, 
we have shown that the important role of 
Phe25 in 14-3-3σ dimerization is due to its 
physical location, rigidity, size, and 
hydrophobicity although it is not located in 
the hydrophobic core. Mutation of Phe25 in 
both subunits results in loosely-packed cores, 
which lead to lost affinity between the two 
opposing subunits.  
Because Val81 and Phe25 both have 
similar total and percentage of surface areas 
that become buried upon dimerization as 
discussed above (see also Table 2), it is of 
interest to investigate the structural basis for 
the difference between Phe25 and Val81 in 
contributing to dimerization. For this purpose, 
we performed 20-ns MD simulations of both 
WT/V81G and WT/F25G dimers as well as 
WT/WT dimer followed by calculation of the 
total binding free energies. Because the 
purpose of the study is for comparison 
between wild type and mutant proteins, we 
omitted the entropy term. The calculated total 
binding free energy represents only the 
enthalpy term. While WT/V81G has a total 
calculated binding free energy of -35.49 
kcal/mol, which is comparable to the total 
binding free energy of WT/WT at -39.77 
kcal/mol, the calculated binding free energy 
of WT/F25G is much higher at -27.81 
kcal/mol (19).  
To investigate the effect of mutations 
on the stability of the core residues, root 
mean square fluctuation (RMSF) of each core 
residue including atoms on both main and 
side chains were calculated from the 
simulations. As shown in Fig. 3, although 
F25G mutation was introduced into only 
subunit II, which directly affected core II 
consisting of A58, L62, Y84 and V88 of subunit 
I and K9, L12, A13 and A16 of subunit II,  the 
stability of residues in core I was also 
affected. As a result, the average RMSF of 
core residues in WT/F25G is 0.66. In contrast, 
the core residues of WT/V81G and WT/WT 
dimers are stable and both have the same 
lower average RMSF of 0.56. 
Dimerization of 14-3-3σ with 
mutations in both dimeric interfaces. In 
above studies using co-immunoprecipitation 
of two differentially tagged proteins, we 
found that L12G, F25G, and Y84G mutants 
could not dimerize with the wild type 14-3-
3σ. However, in our computational analyses 
of the mutant 14-3-3σ, we found that both 
L12G and Y84G mutants appear to have some 
affinity to itself (19). Thus, we next tested if 
these mutant 14-3-3σ can form homo-dimers 
or dimerize with other mutants to form 
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hetero-dimers. These possible combinations 
of dimers carry the same or different 
mutations in one or both interfacial cores (Fig. 
4A). For this purpose, Myc-tagged L12G, 
F25G, and Y84G mutants were transiently 
transfected into the corresponding cells with 
stable expression of the same mutant tagged 
with Flag epitope followed by co-
immunoprecipitation with Flag antibody and 
Western blot analysis with Myc and Flag 
antibody. As shown in Fig. 4B, the non-core 
mutant (F25G) did not form any mutant 
homo-dimer, consistent with the finding 
using non-denaturing PAGE analysis shown 
in Fig. 3. However, the mutants of the 
hydrophobic core residues (L12G and Y84G) 
formed homo-dimers with itself although 
formation of the mutant homo-dimers 
appeared to be less than the wild type homo-
dimer (Fig. 4B).  
We next determined dimerization 
between different mutants using the same 
approach as described above. As shown in 
Fig. 4C, the L12G/Y84G dimer was detected 
albeit at lower level compared with wild type 
proteins. However, no F25G/L12G or 
F25G/Y84G hetero-dimers were detected. 
Together with the data shown in Fig. 4B, 
these observations suggest that F25G mutation 
completely eliminated its dimerization 
activity whereas L12G and Y84G mutants 
retained some of their activities to dimerize 
with itself or each other but not with wild 
type or F25G mutant 14-3-3σ. The lack of 
interaction between wild type and L12G or 
Y84G mutants may be due to the reduced 
dimerization activity of the mutants which 
cause unfavorable kinetics in dimerization 
with and competing for the wild type 
molecules which have higher affinity for 
itself (see Discussion below). 
Monomeric 14-3-3σ may not be 
functional. Previously, we found that over-
expression of 14-3-3σ caused cellular 
resistance to anticancer drugs such as 
mitoxantrone and to γ-irradiation (8,15,20). 
The above studies showed that while wild 
type 14-3-3σ could form strong homo-dimers, 
the hydrophobic core mutants L12G and Y84G 
have weaker interactions and form much less 
homo-dimers compared with the wild type 
protein. The non-core F25G mutant, on the 
other hand, could not form any detectable 
homo-dimers. We next wanted to determine 
if the monomeric 14-3-3σ is functional. For 
this purpose, we first established stable PaCa-
2 cell lines transfected with wild type or 
mutant 14-3-3σ with similar expression 
levels (Fig. 5A). These cell lines were then 
subjected to SRB assay to determine their 
relative resistance to mitoxantrone. As shown 
in Fig. 5B-C, expression of the wild type 14-
3-3σ caused a 3-fold increase in resistance 
compared with the vector-transfected control 
cell that does not express any detectable 14-
3-3σ, consistent with our previous findings 
(8,15,20). However, ectopic over-expression 
of F25G and Y84G mutants had no significant 
effect on cellular resistance to mitoxantrone. 
Interestingly, the stable cell line with L12G 
mutant had a low but significant resistance to 
mitoxantrone compared to the vector-
transfected control cell. This observation is 
consistent with the fact that L12G has the 
most remaining dimerization activity among 
all three mutants. Together, these findings 
indicate that the monomeric mutant 14-3-3σ 
may not be functional in causing cellular 
resistance to anticancer drugs. 
To further determine if monomeric 
14-3-3σ is functional, we chose to analyze 
F25G as a representative in more detail in the 
following experiments. In a previous report, 
we showed that over-expression of 14-3-3σ 
contributes to resistance to γ-irradiation (20). 
To determine if 14-3-3σ-mediated radiation 
resistance also requires dimeric 14-3-3σ, we 
performed colonogenic assay following γ-
irradiation using PaCa-2 cells with stable 
expression of wild type and F25G mutant 14-
3-3σ. As shown in Fig. 5D, PaCa-2 cells with 
wild type 14-3-3σ were significantly more 
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resistant to γ-irradiation than the vector-
transfected control cells. However, PaCa-2 
cells expressing the mutant F25G had similar 
sensitivity to γ-irradiation as the vector-
transfected control cells. Thus, dimerization 
is likely also required for the function of 14-
3-3σ in resistance to γ-irradiation. 
Reduced function of monomeric 14-3-
3σ in resisting drug-induced apoptosis and 
G2/M arrest. Previously, it has been shown 
that the molecular basis of 14-3-3σ function 
in drug and radiation resistance is due to its 
role in regulating DNA-damage-induced 
apoptosis and cell cycle arrest (1). To 
determine if the monomeric mutant 14-3-3σ 
retains any of its function in cellular response 
to drug-induced apoptosis and G2/M arrest, 
we treated PaCa-2 cell lines with stable 
expression of wild type and mutant 14-3-3σ 
as well as vector-transfected control cells 
with mitoxantrone and then determined 
cleavage of PARP, a target substrate of 
activated caspases. Fig. 6 shows a time 
course of production of the cleaved 85-kDa 
PARP fragment induced by mitoxantrone. It 
appears that the wild type as well as all 
mutant 14-3-3σ molecules could slow down 
the production of the 85-kDa PARP fragment 
compared with the vector-transfected control 
cells. At 6 hrs of mitoxantrone treatment, all 
PARPs have been cleaved in the vector-
transfected control cells. At 9-hrs of 
treatment, the stable cells expressing F25G 
and Y84G mutants had >80% of PARPs 
cleaved. However, stable cells with wild type 
and L12G mutant had only ~50% PARPs 
cleaved following 9-hrs of mitoxantrone 
treatment. These observations suggest that 
the monomeric mutant 14-3-3σ has reduced 
activity to resist drug-induced apoptosis. The 
L12G mutant retains more activity in resisting 
drug-induced apoptosis than the other 
mutants, consistent with the observation that 
it maintains more dimerization activity than 
the other mutant molecules.  
Next, we tested activity of the 
monomeric mutant 14-3-3σ in regulating 
G2/M arrest in response to DNA damages. 
Following mitoxantrone treatment, PaCa-2 
cell lines with stable expression of wild type 
and mutant 14-3-3σ as well as vector-
transfected control cells were tested for their 
cell cycle distribution. As shown in Fig. 7A-
B, all cells had similar cell cycle distribution 
under the control growth condition. However, 
following mitoxantrone treatment cells 
expressing wild type 14-3-3σ have ~51% 
cells arrested in G2/M phase compared with 
~24% of vector-transfected control cells. 
Cells expressing the mutant 14-3-3σ had ~36-
42% cells in G2/M phase with the L12G 
mutant having the highest G2/M population 
among all mutant molecules. Thus, the 
monomeric mutant 14-3-3σ is less efficient 
than the wild type dimeric 14-3-3σ in 
arresting cells in G2/M phase in response to 
DNA-damaging treatment.  
Previously, it has been shown that 14-
3-3σ arrests cells in G2/M phase possibly by 
retaining cdc2 in cytoplasm (8). To determine 
if the mutant 14-3-3σ possibly lost this 
activity, we performed an indirect 
immunofluorescence staining of PaCa-2 cells 
with stable expression of wild type and F25G 
mutant 14-3-3σ. Fig. 7C shows that cdc2 is 
located in cytoplasm in both cells under 
control conditions. However, cdc2 moved 
into nucleus in cells with F25G mutant 14-3-
3σ but remained in cytoplasm in the cells 
with wild type 14-3-3σ. This observation 
suggests that the F25G mutant likely lost its 
ability to bind and retain cdc2 in cytoplasm 
in response to DNA-damaging treatment. 
X-ray scattering analysis. The 
observation that L12G mutant has residual 
activity in forming homo-dimers and 
contributing to drug resistance prompted us 
to further analyze the distribution of 
monomers vs dimers using small angle x-ray 
scattering (SAXS) approach, which can be 
used to quantify the molecular weight for a 
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single component system and concentration 
of individual components in a mixture. For a 
single component system, the forward 
scattering relates with the molecular weight 
of a protein by ܫ݋/ܥ௠௔௦௦ 	ൌ 	݇ ൈ ܯݓ, where 
Cmass is the mass concentration (e.g., in 
mg/ml) and k is a constant (31).  If a system 
has more than one component, the apparent 
forward scattering will be the summation of 
that of individual components, i.e., ܫ݋_ܽ݌݌ ൌ
∑ ܫ݋௝௝ . For a monomer-dimer mixture, the 
apparent forward scattering relates with the 
percentage (x) of dimer in mass concentration 
as a function of ܫ݋௔௣௣ ൌ 0.5݇	ܯݓௗ௜௠௘௥ሺ1 ൅
ݔሻ, which is used to estimate the percentage 
of dimers in solution.  
For SAXS determination, we 
engineered the mutations for production and 
purification of recombinant proteins (Fig. 
8A). Because the F25G mutant does not form 
any homo-dimers and has no detectable 
function (see above), we performed SAXS 
analysis only on purified L25G and Y84G 
mutants in comparison with the wild type 14-
3-3σ protein (Fig. 8B). Assuming that all 
molecules of the wild type 14-3-3σ protein 
are dimeric, L12G and Y84G were estimated 
to have 76% and 58% molecules in dimeric 
form, respectively, using the above equation. 
The less dimeric form for Y84G compared 
with L12G in solution is also supported by its 
smaller apparent Rg (Fig. 8C) and shorter-
distance shifted PDDF than that of L12G (Fig. 
8D).  
X-ray scattering (small- and wide-
angle) measures the protein structural details 
at various levels (32). The small-angle region, 
i.e., q<0.3 Å-1, delineates the global shape of
the protein, while the wide -angle data reflect 
the tertiary structure (ca. 0.3<q<1.0 Å-1) and 
features within secondary structure motifs (ca. 
1.0 < q < 2.0 Å-1). The changes in the small-
angle region for the mutants are likely due to 
existence of monomers of the mutant proteins 
(Fig. 8B). However, in the wide-angle region, 
the scattering profiles of mutants are almost 
identical to that of the wild-type protein, with 
both resembling the simulated curves for MD 
structure models, indicating that the 
mutations do not alter the three-dimensional 
structures of the protein.          
Discussion 
In this study, we investigated the role 
of four interfacial amino acid residues (Leu12, 
Phe25, Val81, and Tyr84) in 14-3-3σ 
dimerization and if 14-3-3σ function requires 
the dimerization status.  We found that while 
the interfacial hydrophobic core residues 
Leu12 and Tyr84 played important roles in 14-
3-3σ dimerization, the non-core residue Phe25 
appeared to be more important in controlling 
14-3-3σ dimerization activity. Interestingly, a 
similar non-core residue Val81 was less 
important than Phe25 in contribution to 14-3-
3σ dimerization. Furthermore, dissociating 
dimeric 14-3-3σ into monomers by mutating 
the important dimerization residues Leu12, 
Phe25, or Tyr84 significantly diminished the 
function of 14-3-3σ in resisting drug-induced 
apoptosis and in arresting cells at G2/M phase 
in response to DNA-damaging treatments and, 
thus, in drug and radiation resistance. 
Although both L12G and Y84G 
mutants retain some affinity to itself, neither 
could potentially form detectable dimers with 
wild type or with the F25G mutant 14-3-3σ. 
These two mutants could also dimerize 
between each other and form L12G/Y84G 
hetero-dimers. It appears that the 
dimerization affinity of 14-3-3σ molecules 
occur in the following order: WT/WT > 
L12G/L12G > Y84G/Y84G ≈ L12G/Y84G > 
F25G/F25G ≈ L12G/F25G ≈ Y84G/F25G ≈ 
WT/mutants. This order of observation is 
interesting and may be due to the fact that 
wild type has a much higher dimerization 
activity than any mutants and, thus, 
kinetically more favorable to form dimers 
with wild type than to mutant molecules 
when both wild type and mutant molecules 
are present. Mutant molecules, on the other 
10 
hand, have low dimerization activity and, 
thus, form less dimers between themselves 
than wild type to wild type. Consistent with 
this observation, the calculated binding 
energies from MD simulation for wild 
type/wild type and mutant/mutant dimers are 
also in the same order (19). The F25G mutant 
appears to have lost all of its ability to 
dimerize with itself or with wild type and 
other mutant 14-3-3σ molecules. Thus, the 
Phe25 residue is very critical to 14-3-3σ 
dimerization. These findings also suggest that 
disrupting the function of Phe25 by small 
molecules may be able to completely 
dissociate 14-3-3σ dimerization and that it 
may be targeted for drug discovery.  
It is noteworthy that the V81G mutant 
behaves very differently from the F25G 
mutant although both have similar buried 
surface areas upon dimerization and not 
localized in the interfacial core (Table 2). 
While the F25G mutant completely lost its 
dimerization activity with itself, other 
mutants, or the wild type protein, the V81G 
mutant retains activity to hetero-dimerize 
with the wild type 14-3-3σ. Previously, we 
found that mutation of Phe25 caused 
disruption of the dimeric interface and 
shifting of side chains of Lys9. However, 
mutation of Val81 does not appear to affect 
hydrophobic core residues in the dimeric 
interface as revealed by structural analysis 
using MD simulation. It is also noteworthy 
that the two subareas of the dimeric interface 
are both important and one intact subarea 
does not appear to be sufficient to maintain 
the full dimerization activity. In fact, the 
mutant proteins carrying mutations in the 
same subarea (e.g., L12G/Y84G heterodimer) 
did not form more dimers than the ones with 
mutations in both subareas (e.g., L12G/L12G) 
(see Fig. 4A). Thus, we conclude that both 
subareas of the dimeric interface are required 
to maintain a full dimerization activity of 14-
3-3σ and maintaining one intact subarea has 
no advantage over mutations in both subareas. 
In functional studies, we found that 
the L12G mutant has detectable activity in 
causing resistance, change in apoptosis and 
G2/M arrest. This finding is interesting in that 
the L12G mutant has the highest activity in 
formation of L12G/L12G homo-dimers among 
the three mutants tested, confirming that 
dimerization status is required for the 
function of 14-3-3σ. It is noteworthy that the 
drug resistance activity of L12G mutant is 
much less than the wild type protein although 
76% of purified L12G is estimated to exist as 
homo-dimers. This discrepancy may be due 
to over-estimation of homo-dimers for the 
mutant molecule because it was calculated 
with an assumption that 100% of wild type 
14-3-3σ exists as homo-dimers, which is 
unlikely the case (see Fig. 2). Potential non-
specific interactions at high concentrations of 
purified proteins for SAXS determination 
may also contribute to the higher estimation 
of homo-dimeric mutant molecules. 
Nevertheless, lower level (58%) of homo-
dimers for the Y84G mutant was detected, 
consistent with the observation using co-IP 
and its lack of drug resistance activity. 
Alternatively, the above discrepancy may 
also be due to the possibility that the 
mutations directly affect the functionality of 
the protein in addition to its effect on 
dimerization. However, because 14-3-3σ 
exerts its activity by functioning as a 
chaperone to bind to its ligand proteins and 
these mutations are far away from the ligand-
binding site, it is unlikely that these 
mutations have any direct effect on ligand-
binding activity of 14-3-3σ. Indeed, MD 
simulation analysis showed that these 
mutations do not affect the conformation of 
the ligand-binding domain of 14-3-3σ (19) 
although these observations of computational 
analyses have not yet been validated 
experimentally. However, the data from 
wide-angle x-ray scaterring analyses of the 
purified recombinant proteins suggest that 
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these mutations do not cause major 
conformational change to 14-3-3σ.  
Previously, it was found that the 
monomeric mutant of drosophila 14-3-3ζ 
appears to be functional and may still bind to 
its drosophila ligand Slob (33). However, in 
another study of mammalian 14-3-3ζ, it was 
found that dimerization of 14-3-3ζ is 
dependent on the phosphorylation of the 
Ser58 (34), which is absent in 14-3-3σ, and 
the dimerization is required for its activity in 
binding phosphorylated peptides and protein 
ligands (35). Interestingly, the dimerization 
deficient 14-3-3ζ is able to bind to 
unphosphorylated proteins. In our study, we 
also observed that the F25G mutant 14-3-3σ 
can still bind to a group of proteins 
(unpublished observations) despite the fact 
that it cannot form homo-dimers. It is, thus, 
possible that the dimerization deficient 
mutant 14-3-3σ is unable to bind to its natural 
phosphorylated protein ligands to exert its 
normal functions in contributing drug and 
radiation resistance due to binding to other 
proteins. This is supported by the observation 
that the F25G mutant lost its ability to bind 
and arrest cdc2 in cytoplasm in response to 
DNA damage. Clearly, further work is 
needed to test this possibility. 
In summary, both intact subareas of 
the dimeric interface appear to be required to 
maintain the full dimerization activity of 14-
3-3σ and mutation of hydrophobic core 
residues in any one of these subareas 
diminishes the dimerization activity. In 
addition to the core residues, the non-core 
residue Phe25 also plays an important role in 
driving 14-3-3σ dimerization by organizing 
other hydrophobic core residues. However, 
another similar non-core residue Val81 is 
much less important and its mutation does 
not affect the dimerization activity of 14-3-3σ. 
The dimerization deficient 14-3-3σ also lost 
their function in causing drug and radiation 
resistance. Based on these findings, it is 
tempting to speculate that targeting any one 
of these important residues may help identify 
inhibitors that can disrupt 14-3-3σ 
dimerization for drug discovery to sensitize 
14-3-3σ-mediated resistance in cancer 
treatments. The outcome of this study may 
help drug the “undruggable” oncogenic 
protein dimers in general. 
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FIGURE LEGENDS 
Figure 1. Interaction between mutant and wild type 14-3-3σ. A. Schematic diagram of 
tagged 14-3-3σ constructs and dimeric 14-3-3σ molecules with mutated residues indicated. A 14-
3-3σ dimer has two equivalent subareas in the interface with 180o symmetry. B and C. 
Interaction between HA-tagged wild type and HAM2-tagged mutant 14-3-3σ molecules in whole 
cell (B) and cell-free (C) systems. HEK293 cells with stable expression of HA-tagged wild type 
14-3-3σ were transiently transfected with HAM2-tagged wild type or mutant 14-3-3σ (B) or both 
HA- and HAM2-tagged wild type and mutant 14-3-3σ transcripts were co-translated in rabbit 
reticulocyte lysates (C) as indicated followed by co-immunoprecipitation with Myc antibody. 
The precipitates were then subjected to Western blot analysis probed with HA antibodies to 
detect both HAM2- and HA-tagged proteins. The asterisks indicate the co-precipitated HA-
tagged wild type 14-3-3σ proteins. The broad bands for L12G, F25G, V81G, and Y84G mutant 
proteins shown in panel B are likely due to degradation. 
Figure 2. Non-denaturing PAGE analysis of dimerization activity of wild type and 
Phe25 mutant 14-3-3σ. HAM2- and HA-tagged wild type and mutant 14-3-3σ transcripts were 
co-translated in rabbit reticulocyte lysate followed by separation of the products using non-
denaturing PAGE and Western blot analysis of dimeric and monomeric 14-3-3σ proteins probed 
with HA (upper panel) or Myc (lower panel) antibodies for HA- and HAM2-tagged molecules. 
The asterisks indicate wild type HAM2/HAM2 (upper band) HAM2/HA (middle band), and 
HA/HA (lower band) 14-3-3σ dimers with different mobility due to different sizes of the tags 
used. 
Figure 3. RMSF of core residues in both subunits. Amino acid residues that constitute 
hydrophobic cores are indicated at the top. Single underlined residues are for core I and double 
underlined ones are for core II. 
Figure 4. Homo- and hetero-dimerization between the mutant 14-3-3σ proteins. A. 
Schematic diagram of the relative position of mutations in the two subareas of the interface 
between homo- and hetero-mutant 14-3-3σ dimers. B and C. Homo- (B) and hetero- (C) 
dimerization of mutant 14-3-3σ. Mia PaCa-2 cells with sable expression of Flag-tagged wild type 
or mutant 14-3-3σ were transiently transfected with or without Myc-tagged wild type or mutant 
14-3-3σ as indicated followed by immunoprecipitation with Flag antibody. The precipitates were 
then subjected to Western blot analysis probed with Flag or Myc antibody.  
Figure 5. Dimerization is required for 14-3-3σ-mediated drug resistance. A. Western 
blot analysis of stable PaCa-2 cell lines transfected with vector (Vec) control, wild type and 
mutant 14-3-3σ. Actin was used as a loading control. B, C, and D. Survival analysis. Stable cell 
lines as shown in panel A were treated with different concentrations of mitoxantrone (MXT, B 
and C) or with or without 2 Gy γ-irradiation (D) followed by SRB assay (B and C) or colony 
formation assay (D). Panel B represents a typical experiment of survival assay. Panels C and D 
are summary of 3-4 experiments. RRF=relative resistance factor=IC50(MXT)/IC50(Vec). *p<0.05, 
**p<0.01. 
Figure 6. Effect of dimerization deficiency on drug-induced apoptosis. A. Western 
blot analysis of PARP cleavage in stable PaCa-2 cell lines transfected with vector (Vec) control, 
wild type and mutant 14-3-3σ following mitoxantrone treatment at different times. B. 
Quantitative analysis of cleaved PARP. The intact (115 kDa) and cleaved (85 kDa) PARP shown 
in panel A was quantified using a gel densitometer and the ratio of 85 kDa/Total (85 kDa+115 
kDa) was calculated to serve as an indicator of apoptosis. 
15 
Figure 7. Effect of dimerization deficiency on drug-induced G2/M arrest. A. FACS 
analysis of cell cycle distribution of stable PaCa-2 cell lines transfected with vector (Vec) 
control, wild type and mutant 14-3-3σ following treatment with 10 nM mitoxantrone (MXT) or 
DMSO control for 3 days. B. Quantitative analysis of cell cycle distribution as shown in panel A. 
C. Immunoflurescence staining of cdc2. PaCa-2 cells with stable expression of wild type (WT) 
and mutant (F25G) 14-3-3σ were treated with DMSO control or 10 nM mitoxantrone (MXT) for 
3 days followed by immunofluorescence staining of cdc2. 
Figure 8. Purification and x-ray scattering analyses of wild type and mutant 14-3-3σ 
proteins. A. SDS-PAGE profiles of purified wild type, L12G, and Y84G mutant 14-3-3σ stained 
with commassie blue. B. Small- and wide-angle x-ray scattering profiles for wide-type and 
mutant 14-3-3σ proteins. The black and cyan lines represent simulated profiles of dimeric and 
monomeric molecules, respectively, generated using MD simulation. The red, blue, and green 
lines represent profiles of wild-type, L12G and Y84G mutant molecules, respectively, determined 
using x-ray scattering.  The profiles were vertically offset for clarity. C. Guinier plots of wild-
type (red), L12G (blue) and Y84G (green) mutants using scattering data from panel B normalized 
by mass concentration. D. Normalized pair distance distribution functions (PDDF) of wild-type 
(red), L12G (blue) and Y84G (green) mutant 14-3-3σ. The PDDFs were calculated with program 
GNOM using scattering data (q range up to 0.3Å-1 from panel B.  
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Table 1. Primers used for engineering 14-3-3σ constructs 
Tags/Mutations Primers 




Myc  5’-GGAATTCATGGAGAGAGCCAGTCTG-3’ 
5’-GCTCGAGTCACAGATCTTCTTCAGAAATAAGTTTTTGTTCGCTCTGGGGCTCCTGGGGAGC-3’ 
HAM2  5’-GGAATTCATGGAGAGAGCCAGTCTG-3’ 
5’-GCTCGAGTCACAGATCTTCTTCAGAAATAAGTTTTTGTTCCAGATCTTCTTCAGAAATAAGTTTTTGT 
TCGAGGCTAGCATAATCAGG-3’ 
Q8G  5’-GGAATTCATGGAGAGAGCCAGTCTG-3’ 
5’-ATGGAGAGAGCCAGTCTGATCGGGAAGGCCAAGCTGGCAGAGC-3’ 
L12G  5’-ATGGAGAGAGCCAGTCTGATCCAGAAGGCCAAGGGGGCAGAGCAGGCCGAACG-3’ 
5’-CGTTCGGCCTGCTCTGCCCCCTTGGCCTTCTGGATCAGACTGGCTCTCTCC-3’ 
F25G  5’-ATGAGGACATGGCAGCCGGCATGAAAGGCGCCGTGGA-3’ 
5’-CCACGGCGCCTTTCATGCCGGCTGCCATGTCCTC-3’ 
F25E  5’-ATGAGGACATGGCAGCCGAGATGAAAGGCGCCGTGGA-3’ 
5’-CCACGGCGCCTTTCATCTCGGCTGCCATGTCCTC-3’ 
 V81G  5’-CGGAGGAGAAGGGGCCCGAGGGGCGTGAGTACCGGGAGAAGG-3’ 
5’-CCTTCTCCCGGTACTCACGCCCCTCGGGCCCCTTCTCCTCCG-3’ 
Y84G  5’-GGGCCCGAGGTGCGTGAGGGCCGGGAGAAGGTGGAGAC-3’ 
5’-GTCTCCACCTTCTCCCGGCCCTCACGCACCTCGGGCCC-3’  
 at Indiana University School of Medicine on September 9, 2015 http://www.jbc.org/ Downloaded from 
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Table 2. Residues important for dimer formation 
Rankingsa Residues Buried Surface Areab Core vs non-Core 
1 TYR84 120 (99%) Core 
2 LEU12 88 (96%) Core
3 ALA16 58 (91%) Core 
4 LYS9 70 (83%) Core
5 ALA58 36 (100%) Core 
6 LEU62 25 (100%) Core
7 PHE25 25 (53%) non-Core 
8 VAL81 24 (42%) non-Core
9 GLN8 23 (25%) non-Core 
10 VAL88 14 (100%) Core
11 ALA13 9 (100%) Core 
aThe rankings are based on buried surface areas at the dimeric interface each residue provides. 
bBuried surface areas, in A2, represents the surface area that becomes buried upon dimerization. 
The percentage of buried surface area=Surface area that becomes buried upon dimerization/Total 
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